Clinical trial
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent…
NCT00124943 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00124943 |
|---|---|
| Title | Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis |
| Official title | A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis |
| Acronym | SNAPIST-III |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Restenosis |
| Intervention type | Drug |
| Interventions | Nanoparticle Paclitaxel |
| Enrollment | 112 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Jul 29, 2005 |
| Last update posted | Apr 2, 2012 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: